New weapon against cancer enters human testing
NCT ID NCT05565417
Summary
This is an early-stage study testing a new antibody drug called IMT-009 in people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand the side effects, and see if the drug helps shrink tumors. The study will involve about 67 participants and will test the drug alone and later in combination with another cancer therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 3000
Nashville, Tennessee, 37203, United States
-
Site 4060
Sarasota, Florida, 34232, United States
-
Site 4100
Orlando, Florida, 32827, United States
-
Site 4500
Oklahoma City, Oklahoma, 73104, United States
-
Site 5000
Denver, Colorado, 80218, United States
-
Site 9112
Fairfax, Virginia, 22031, United States
-
Site 9280
Portland, Oregon, 97239, United States
-
Site 9384
Austin, Texas, 78705, United States
-
Site 9618
Tucson, Arizona, 85711, United States
Conditions
Explore the condition pages connected to this study.